Sep 1, 2026Alumis experimental lupus drug fails primary endpoint in phase 3 trialAlumis reported its experimental TYK2 inhibitor failed to meet the main goal of a late-stage lupus trial, though the company plans to advance the drug in a smaller subset of patients.Sep 1, 2026·2 sources00
Apr 6, 2026Scripps Research Develops New Anti-Inflammatory Drug Class That Preserves Immune FunctionScripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.Apr 6, 2026·1 source00
